(original) (raw)

TY - JOUR AU - Buckanovich, Ronald J AU - Facciabene, Andrea AU - Kim, Sarah AU - Benencia, Fabian AU - Sasaroli, Dimitra AU - Balint, Klara AU - Katsaros, Dionysios AU - O'Brien-Jenkins, Anne AU - Gimotty, Phyllis A AU - Coukos, George PY - 2008 DA - 2008/01/01 TI - Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy JO - Nature Medicine SP - 28 EP - 36 VL - 14 IS - 1 AB - In spite of their having sufficient immunogenicity, tumor vaccines remain largely ineffective. The mechanisms underlying this lack of efficacy are still unclear. Here we report a previously undescribed mechanism by which the tumor endothelium prevents T cell homing and hinders tumor immunotherapy. Transcriptional profiling of microdissected tumor endothelial cells from human ovarian cancers revealed genes associated with the absence or presence of tumor-infiltrating lymphocytes (TILs). Overexpression of the endothelin B receptor (ETBR) was associated with the absence of TILs and short patient survival time. The ETBR inhibitor BQ-788 increased T cell adhesion to human endothelium in vitro, an effect countered by intercellular adhesion molecule-1 (ICAM-1) blockade or treatment with NO donors. In mice, ETBR neutralization by BQ-788 increased T cell homing to tumors; this homing required ICAM-1 and enabled tumor response to otherwise ineffective immunotherapy in vivo without changes in systemic antitumor immune response. These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans. SN - 1546-170X UR - https://doi.org/10.1038/nm1699 DO - 10.1038/nm1699 ID - Buckanovich2008 ER -